|Chemical and physical data|
|Molar mass||423.600 g·mol−1|
|3D model (JSmol)|
JWH-371 ([5-(4-butylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone) is a synthetic cannabinoid from the naphthoylpyrrole family which acts as an agonist of the CB1 (Ki = 42 ± 1nM) and CB2 (Ki = 64 ± 2nM) receptors, binding ~1.5 times stronger to the CB1 receptor than the CB2 receptor. JWH-371 was first synthesized in 2006 by John W. Huffman and colleagues to examine the nature of ligand binding to the CB1 receptor.
In the United States JWH-371 is not federally scheduled, although some states have passed legislation banning the sale, possession, and manufacture of JWH-371.
In Canada, JWH-371 and other naphthoylpyrrole-based cannabinoids are Schedule II controlled substances under the Controlled Drugs and Substances Act.
In the United Kingdom, JWH-371 and other naphthoylpyrrole-based cannabinoids are considered Class B drugs under the Misuse of Drugs Act 1971.
- ^ Huffman JW, Padgett LW, Isherwood ML, Wiley JL, Martin BR (October 2006). "1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors". Bioorganic & Medicinal Chemistry Letters. 16 (20): 5432–5. doi:10.1016/j.bmcl.2006.07.051. PMID 16889960.
- ^ 21 U.S.C. § 812: Schedules of controlled substances
- ^ "The 2020 Florida Statutes". www.leg.state.fl.us. Retrieved 20 August 2021.
- ^ "Arizona Revised Statutes Title 13. Criminal Code § 13-3401". www.azleg.gov. Retrieved 20 August 2021.
- ^ "California Code, Health and Safety Code - HSC § 11357.5". Findlaw.